History
# Registration date Revision Id
2 2020-09-06, 1399/06/16 149876
1 2019-12-13, 1398/09/22 113756
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    Effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory and anti-inflammatory markers in patients with Non-alcoholic fatty liver
    Effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory, anti-inflammatory, immune markers and mental health in patients with Non-alcoholic fatty liver
    تعیین تاثیر روغن کاملینا با و بدون مکمل یاری دکسترین مقاوم بر شاخصهای متابولیکی، التهابی، ضد التهابی در بیماران مبتلا به کبد چرب غیر الکلی
    تعیین تاثیر روغن کاملینا با و بدون مکمل یاری دکسترین مقاوم بر شاخصهای متابولیکی، التهابی، ضد التهابی، ایمنی و سلامت ذهنی در بیماران مبتلا به کبد چرب غیر الکلی
  • General information

    empty
    No changes have been made in the protocol of the present study, and only some parameters have been added. According to the comprehensive review on registered trial, all the added parameters along with the recorded parameters were presented as a comprehensive study in this field. Unfortunately, before registering this project in the Iranian Registry of Clinical Trials due to financial constraints, some of the considered parameters were removed. Recently, due to the funding of the project via top researchers grant, researchers have re-added the deleted parameters to the project for a comprehensive study in this field.
    empty
    تغییراتی در پروتکل مطالعه حاضر انجام نیافته است وفقط برخی پارامترها اضافه شده اند. بر طبق مرور بر متون جامع محققین، کلیه پارامترهای اضافه شده همراه با پارامترهای ثبت شده به صورت یک طرح جامع ارایه گردیده بود. اما قبل از ثبت این طرح در مرکز کارآزمایی های بالینی بواسطه محدودیت مالی، پاره ای از پارامترهای مورد مطالعه حذف گردید. اخیرا بواسطه تامین مالی طرح در قالب گرنت پژوهشی محققین برتر، محققین پارامترهای محذوف را مجددا به طرح اضافه نموده اند تا یک مطالعه جامع در این زمینه صورت پذیرد .
  • Primary outcomes

    #1
    empty
    Total antioxidant capacity
    empty
    ظرفیت آنتی اکسیدانی تام
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #2
    empty
    Malondialdehyde
    empty
    مالون دی آلدئید
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #3
    empty
    8-iso-prostaglandin F2α (8-iso-PGF2α)
    empty
    8-ایزوپروستاگلاندین F2α
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #4
    empty
    superoxide dismutase
    empty
    سوپر اکسید دیس موتاز
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #5
    empty
    leptin
    empty
    لپتین
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #6
    empty
    adiponectin
    empty
    ادیپونکتین
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #7
    empty
    ghrelin
    empty
    گرلین
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #8
    empty
    PPAR-α expression
    empty
    وضعیت اشتها
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #9
    empty
    mental health
    empty
    سلامت روان
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    questionnaires
    empty
    پرسشنامه ها
    #10
    empty
    lipopolysaccharide
    empty
    لیپو پلی ساکارید
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #11
    empty
    cd4
    empty
    cd4
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #12
    empty
    cd8
    empty
    cd8
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #13
    empty
    ILB1
    empty
    اینترلوکین 1
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #14
    empty
    Brain-derived Neurotrophic Factor
    empty
    فاکتور نوتروفیک مشتق شده از مغز
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #15
    empty
    il17
    empty
    il17
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    kit
    empty
    كيت اختصاصي
    #16
    empty
    PPAR-α expression
    empty
    بیان ژن PPAR-α
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    pcr
    empty
    pcr
  • Secondary outcomes

    #1
    empty
    body composition
    empty
    ترکیب بدن
    empty
    At baseline and three months after baseline
    empty
    ابتدا و سه ماه بعد از شروع مطالعه
    empty
    BIA devices
    empty
    دستگاه BIA
  • Recruitment centers

    #1
    Name of recruitment center - English: Tabriz International Hospital
    Name of recruitment center - Persian: بیمارستان بین المللی تبریز
    Full name of responsible person - English: ِDr.Manouchehr khoshbaten
    Full name of responsible person - Persian: دکتر منوچهر خوشباطن
    Street address - English: Tabriz International Hospital, First Saffronia, Affliction Square
    Street address - Persian: بیمارستان بین الملل تبریز، اول زعفرانیه، میدان افلاک نما
    City - English: Tabriz
    City - Persian: تبریز
    Province: East Azarbaijan
    Country: Iran (Islamic Republic of)
    Postal code: 5166614711
    Phone: +98 41 3332 8832
    Fax:
    Email: mkhoshbaten@yahoo.com
    Web page address:
    Name of recruitment center - English: Tabriz International Hospital
    Name of recruitment center - Persian: بیمارستان بین المللی تبریز
    Full name of responsible person - English: ِDr.Manouchehr Khoshbaten
    Full name of responsible person - Persian: دکتر منوچهر خوشباطن
    Street address - English: Tabriz International Hospital, First of Zaffaraniyeh, Aflaknema Square
    Street address - Persian: بیمارستان بین الملل تبریز، ابتدای زعفرانیه، میدان افلاک نما
    City - English: Tabriz
    City - Persian: تبریز
    Province: East Azarbaijan
    Country: Iran (Islamic Republic of)
    Postal code: 5166614711
    Phone: +98 41 3332 8832
    Fax:
    Email: mkhoshbaten@yahoo.com
    Web page address:
  • Sponsors / Funding sources

    #1

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Professor Alireza ostad Rahimi
    Full name of responsible person - Persian: دکتر علیرضا استاد رحیمی
    Street address - English: Faculty of Nutrition and Nutrition, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
    Street address - Persian: تبریز، خیابان گلگشت، دانشگاه علوم پزشکی تبریز، دانشکده تغذیه و علوم غذایی
    City - English: Tabriz
    City - Persian: تبریز
    Province: East Azarbaijan
    Country: Iran (Islamic Republic of)
    Postal code: 5166614711
    Phone: +98 41 3335 7581
    Fax:
    Email: ostadrahimi@tbzmed.ac.ir
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Professor Alireza Ostad Rahimi
    Full name of responsible person - Persian: دکتر علیرضا استاد رحیمی
    Street address - English: Faculty of Nutrition and Food science, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
    Street address - Persian: تبریز، خیابان گلگشت، دانشگاه علوم پزشکی تبریز، دانشکده تغذیه و علوم غذایی
    City - English: Tabriz
    City - Persian: تبریز
    Province: East Azarbaijan
    Country: Iran (Islamic Republic of)
    Postal code: 5166614711
    Phone: +98 41 3335 7581
    Fax:
    Email: ostadrahimi@tbzmed.ac.ir
    Web page address:

Protocol summary

Study aim
Effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory, anti-inflammatory, immune markers and mental health in patients with Non-alcoholic fatty liver
Design
a triple blind randomized clinical trial with control group and parallel group. sample size is 32
Settings and conduct
This is a triple blind study in Tabriz University of Medical Sciences.
Participants/Inclusion and exclusion criteria
Inclusion criteria: age 20 to 65 years; BMI≥25; restriction of consumption of edible nuts and fish; propensity to consume camelina and prebiotic oil. Exclusion criteria:Having liver disease other than NAFLD (alcoholic fatty liver, viral hepatitis, cirrhosis and biliary obstruction, liver cancer); liver transplantation; pregnancy; lactation; Kidney; Cardiovascular; Alcohol; Cigarettes & Drugs; High Physical Activity; Acute Disease; Medications Like Glucocorticoids; Last month or special diet; reluctance to take prebiotics and gastrointestinal symptoms; Weight changes in the last 3 months
Intervention groups
Intervention group 1: (Weight loss diet + camelina oil + resistant dextrin + physical activity) Control group: (Weight loss diet + camelina oil + malt dextrin + physical activity)
Main outcome variables
En Alanine amino transferase (ALT); aspartate amino transferase (AST); alkaline phosphatase (ALP); Degree of hepatic steatosis; fasting blood glucose; fasting insulin; insulin resistance; insulin sensitivity; total cholesterol (TC); low triglyceride High density lipoprotein (HDL); tumor necrosis factor-alpha (TNF-α); high-sensitivity c-reactive protein (Hs-CRP); interleukin-10 (IL-10)

General information

Reason for update
No changes have been made in the protocol of the present study, and only some parameters have been added. According to the comprehensive review on registered trial, all the added parameters along with the recorded parameters were presented as a comprehensive study in this field. Unfortunately, before registering this project in the Iranian Registry of Clinical Trials due to financial constraints, some of the considered parameters were removed. Recently, due to the funding of the project via top researchers grant, researchers have re-added the deleted parameters to the project for a comprehensive study in this field.
Acronym
IRCT registration information
IRCT registration number: IRCT20150205020965N4
Registration date: 2019-12-13, 1398/09/22
Registration timing: registered_while_recruiting

Last update: 2020-09-07, 1399/06/17
Update count: 1
Registration date
2019-12-13, 1398/09/22
Registrant information
Name
Parvin Dehghan
Name of organization / entity
Tabriz University Of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 41 3335 7580
Email address
dehghanp@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-11-15, 1398/08/24
Expected recruitment end date
2020-05-13, 1399/02/24
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory and anti-inflammatory markers in patients with Non-alcoholic fatty liver
Public title
The effect of Camelina oil with and without Resistant dextrin supplementation on Non-alcoholic fatty liver
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age range 20 to 65 years BMI≥25 Edible nuts and fish consumption restriction Tendency to use camelina oil and prebiotic Having grade 1 and 2 fatty liver disease
Exclusion criteria:
Having other liver disease apart from NAFLD (alcoholic fatty liver, viral hepatitis, cirrhosis and biliary obstruction, liver cancer) Liver transplantation Pregnancy, Lactation Having kidney, Cardiovascular Disease Alcohol Consumption and smoking High physical activity Having acute illness Use of drugs such as glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDS), hepatotoxic drugs, antibiotics Taking antioxidant supplements and W3 history of losing weight over the past 6 months or a special diet Unwillingness to use prebiotics Gastrointestinal symptoms incidence during the study Weight changes over the past 3 months
Age
From 20 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Investigator
  • Data analyser
Sample size
Target sample size: 32
Randomization (investigator's opinion)
Randomized
Randomization description
At baseline, eligible individuals will be matched for BMI, age, and sex according to the classification of these variables. Individuals will be randomly divided into two groups of 16 intervention (receiving weight loss diet + Camelina oil +Maltodextrin) control (recipient). Weight loss regimen + Camelina oil + Resistant dextrin) divided into 2 and 4 blocks using RAS software and will be given codes 1 and 2.
Blinding (investigator's opinion)
Triple blinded
Blinding description
After randomization, both groups will be fed the camilina oil with identical weight loss regimens with similar recommendations by the expert. Resistant dextrin and maltodextrin will also be encoded in sachets weighing 5 g in similar packages (metallized) by the researcher and coded with codes 1 and 2. Nutritionists will introduce code to patients when giving diet and oil, resistant dextrin and malt dextrin. Until the patient study results are released, the researcher and data analyzer will not be aware of the assigned codes. So the study will be three-blind.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Tabriz University of Medical Sciences
Street address
Central Building No. 2, Tabriz University of Medical Sciences, Golgasht Street, Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711
Approval date
2019-10-20, 1398/07/28
Ethics committee reference number
IR.TBZMED.REC.1398.738

Health conditions studied

1

Description of health condition studied
Non-alcoholic fatty liver
ICD-10 code
K76.0
ICD-10 code description
Fatty (change of) liver, not elsewhere classified

Primary outcomes

1

Description
ALT
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

2

Description
AST
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

3

Description
ALP
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

4

Description
Degree of hepatic steatosis
Timepoint
At baseline and three months after baseline
Method of measurement
sonography

5

Description
Fasting glucose
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

6

Description
Insulin Sensitivity Index (QUICK)
Timepoint
At baseline and three months after baseline
Method of measurement
calculation

7

Description
Insulin Resistance Index (HOMA-IR)
Timepoint
At baseline and three months after baseline
Method of measurement
calculation

8

Description
Fasting insulin
Timepoint
At baseline and three months after baseline
Method of measurement
kit

9

Description
Total -cholesterol
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

10

Description
HDL-cholesterol
Timepoint
At baseline and three months after baseline
Method of measurement
Hitachi 911 auto-analyzer

11

Description
LDL-cholesterol
Timepoint
At baseline and three months after baseline
Method of measurement
calculation

12

Description
Triglyceride
Timepoint
At baseline and three months after baseline
Method of measurement
Autoanalyzer - Hitachi 911

13

Description
Highly sensitive C-reactive protein(hs-CRP )
Timepoint
At baseline and three months after baseline
Method of measurement
Kit

14

Description
Tumor Necrosis Factor (TNF)
Timepoint
At baseline and three months after baseline
Method of measurement
ELISA Kit

15

Description
Interleukin 10(IL10 )
Timepoint
At baseline and three months after baseline
Method of measurement
ELISA Kit

16

Description
Total antioxidant capacity
Timepoint
At baseline and three months after baseline
Method of measurement
kit

17

Description
Malondialdehyde
Timepoint
At baseline and three months after baseline
Method of measurement
kit

18

Description
8-iso-prostaglandin F2α (8-iso-PGF2α)
Timepoint
At baseline and three months after baseline
Method of measurement
kit

19

Description
superoxide dismutase
Timepoint
At baseline and three months after baseline
Method of measurement
kit

20

Description
leptin
Timepoint
At baseline and three months after baseline
Method of measurement
kit

21

Description
adiponectin
Timepoint
At baseline and three months after baseline
Method of measurement
kit

22

Description
ghrelin
Timepoint
At baseline and three months after baseline
Method of measurement
kit

23

Description
PPAR-α expression
Timepoint
At baseline and three months after baseline
Method of measurement
kit

24

Description
mental health
Timepoint
At baseline and three months after baseline
Method of measurement
questionnaires

25

Description
lipopolysaccharide
Timepoint
At baseline and three months after baseline
Method of measurement
kit

26

Description
cd4
Timepoint
At baseline and three months after baseline
Method of measurement
kit

27

Description
cd8
Timepoint
At baseline and three months after baseline
Method of measurement
kit

28

Description
ILB1
Timepoint
At baseline and three months after baseline
Method of measurement
kit

29

Description
Brain-derived Neurotrophic Factor
Timepoint
At baseline and three months after baseline
Method of measurement
kit

30

Description
il17
Timepoint
At baseline and three months after baseline
Method of measurement
kit

31

Description
PPAR-α expression
Timepoint
At baseline and three months after baseline
Method of measurement
pcr

Secondary outcomes

1

Description
Body Mass Index (BMI)
Timepoint
At baseline and three months after baseline
Method of measurement
Calculation

2

Description
Amount of received energy
Timepoint
At baseline and three months after baseline
Method of measurement
Questionnaire

3

Description
Daily carbohydrate intake
Timepoint
At baseline and three months after baseline
Method of measurement
Questionnaire

4

Description
Daily protein intake
Timepoint
At baseline and three months after baseline
Method of measurement
Questionnaire

5

Description
Daily fat intake
Timepoint
At baseline and three months after baseline
Method of measurement
Questionnaire

6

Description
Daily fiber intake
Timepoint
At baseline and three months after baseline
Method of measurement
Questionnaire

7

Description
Weight
Timepoint
At baseline and three months after baseline
Method of measurement
Scale

8

Description
Waist circumference (WC)
Timepoint
At baseline and three months after baseline
Method of measurement
Tape

9

Description
Hip circumference (HC)
Timepoint
At baseline and three months after baseline
Method of measurement
Tape

10

Description
Waist circumference (WHR) ________________________________________
Timepoint
At baseline and three months after baseline
Method of measurement
Calculation

11

Description
Blood pressure
Timepoint
At baseline and three months after baseline
Method of measurement
Mercury barometer

12

Description
body composition
Timepoint
At baseline and three months after baseline
Method of measurement
BIA devices

Intervention groups

1

Description
In this study, Camelina oil will be replaced with 15% of the daily total fat intake and patients will receive two of 5-mg dextrin-resistant doses every day for three months. Then, 15 days before the beginning of study, FFQ questionnaire will be completed for selected patients based on inclusion and exclusion criteria to determine the dietary pattern of patients. Patients will also be asked not to use omega-3 oils (as mentioned in list) ,prebiotic and probiotic sources during this time. Then, basal energy expenditure of each person will be calculated by Mifflin equation based on their weight, age, sex and total energy expenditure will be calculated according to the person's daily physical activity. For losing weight, 500 kcal reduction of total energy expenditure will be done, and then macronutrients will be distributed to 50% carbohydrate, 30% fat, 20% protein, and the proper diet will be adjusted according to one's dietary pattern. 15% of the dietary fat will be provide by Camelina oil (prepared by cold press, rich in omega-3 fatty acids, then will be analyzed before intervention). Patients will be instructed to measure the recommended amount of oil with the modules given with the oil, and add it to their salad or meal every day (while consuming or cooking), and intake the remain amount from dairy fat, meat and other oils. At the same time, patients will be advised to dissolve one serving of powdered sachets (resistant dextrin) in the lukewarm water each time and consume it by food in the morning and night. The oils and powder supplements will be given monthly to patients, and they will be advised to keep the consuming oil inside the refrigerator, depending on the type of processing (cold press). Each week a phone call will be made to ensure adherence to the diet, supplement intake, and patient status assessment will be done. Patients will be asked to deliver the remaining oil and sachet bottles each month to receive the new oil and sachet bottles for the following month to ensure consumption and following them up. Patients will be advised to avoid fried foods, simple carbohydrates, solid oils and will be advised to use steamed foods as much as possible. Patients will be asked to report any gastrointestinal problems or not possibility of oil intake to available numbers. Metabolic, biochemical, anthropometric parameters, blood pressure and dietary intakes will be assessed before and after intervention.
Category
Treatment - Other

2

Description
In this study, Camelina oil will be replaced with 15% of the daily total fat intake and patients will receive two of 5-mg maltodextrin doses every day for three months. Then, 15 days before the beginning of study, FFQ questionnaire will be completed for selected patients based on inclusion and exclusion criteria to determine the dietary pattern of patients. Patients will also be asked not to use omega-3 oils (as mentioned in list) ,prebiotic and probiotic sources during this time. Then, basal energy expenditure of each person will be calculated by Mifflin equation based on their weight, age, sex and total energy expenditure will be calculated according to the person's daily physical activity. For losing weight, 500 kcal reduction of total energy expenditure will be done, and then macronutrients will be distributed to 50% carbohydrate, 30% fat, 20% protein, and the proper diet will be adjusted according to one's dietary pattern. 15% of the dietary fat will be provide by Camelina oil (prepared by cold press, rich in omega-3 fatty acids, then will be analyzed before intervention). Patients will be instructed to measure the recommended amount of oil with the modules given with the oil, and add it to their salad or meal every day (while consuming or cooking), and intake the remain amount from dairy fat, meat and other oils. At the same time, patients will be advised to dissolve one serving of powdered sachets (maltodextrin) in the lukewarm water each time and consume it by food in the morning and night. The oils and powder supplements will be given monthly to patients, and they will be advised to keep the consuming oil inside the refrigerator, depending on the type of processing (cold press). Each week a phone call will be made to ensure adherence to the diet, supplement intake, and patient status assessment will be done. Patients will be asked to deliver the remaining oil and sachet bottles each month to receive the new oil and sachet bottles for the following month to ensure consumption and following them up. Patients will be advised to avoid fried foods, simple carbohydrates, solid oils and will be advised to use steamed foods as much as possible. Patients will be asked to report any gastrointestinal problems or not possibility of oil intake to available numbers. Metabolic, biochemical, anthropometric parameters, blood pressure and dietary intakes will be assessed before and after intervention.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Tabriz International Hospital
Full name of responsible person
ِDr.Manouchehr Khoshbaten
Street address
Tabriz International Hospital, First of Zaffaraniyeh, Aflaknema Square
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711
Phone
+98 41 3332 8832
Email
mkhoshbaten@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Professor Alireza Ostad Rahimi
Street address
Faculty of Nutrition and Food science, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711
Phone
+98 41 3335 7581
Email
ostadrahimi@tbzmed.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Dehghan
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711
Phone
+98 41333340634
Email
dehghan.nut@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Dehghan
Position
Associate Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Faculty of Nutrition and Nutrition, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665931
Phone
+98 41333340634
Email
Dehghan.nut@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Dehghan
Position
Associate Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Faculty of Nutrition and Nutrition, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665931
Phone
+98 41 3334 0634
Email
Dehghan.nut@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Reporting the results
When the data will become available and for how long
after finishing the study and publishing the project articles
To whom data/document is available
Academic researchers
Under which criteria data/document could be used
with permission of Project Researcher and Project Sponsor - Nutrition Research Center
From where data/document is obtainable
Dr Parvin Dehghan, Faculty of Nutrition and Food science, Tabriz University of Medical Sciences Email: Dehghan.nut@gmail.com Phone: +98 914 471 0299
What processes are involved for a request to access data/document
The applicant can send an application to the responsible person by email
Comments
Loading...